These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8136818)

  • 21. Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.
    Jorge A; Ung C; Young LH; Melles RB; Choi HK
    Nat Rev Rheumatol; 2018 Dec; 14(12):693-703. PubMed ID: 30401979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel method for screening the multifocal electroretonogram in patients using hydroxychloroquine.
    Chang WH; Katz BJ; Warner JE; Vitale AT; Creel D; Digre KB
    Retina; 2008; 28(10):1478-86. PubMed ID: 18997610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
    Martínez-Costa L; Victoria Ibañez M; Murcia-Bello C; Epifanio I; Verdejo-Gimeno C; Beltrán-Catalán E; Marco-Ventura P
    Can J Ophthalmol; 2013 Oct; 48(5):400-5. PubMed ID: 24093187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxychloroquine retinopathy.
    Weiner A; Sandberg MA; Gaudio AR; Kini MM; Berson EL
    Am J Ophthalmol; 1991 Nov; 112(5):528-34. PubMed ID: 1951589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy.
    Bernstein HN
    Am J Med; 1983 Jul; 75(1A):25-34. PubMed ID: 6869408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
    Costedoat-Chalumeau N; Dunogué B; Leroux G; Morel N; Jallouli M; Le Guern V; Piette JC; Brézin AP; Melles RB; Marmor MF
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):317-26. PubMed ID: 25672591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy.
    Lai TY; Chan WM; Li H; Lai RY; Lam DS
    Am J Ophthalmol; 2005 Nov; 140(5):794-807. PubMed ID: 16310457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxychloroquine at the recommended dose (< or = 6.5 mg/kg/day) is safe for the retina in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Marmor MF
    Clin Exp Rheumatol; 2004; 22(2):143-4. PubMed ID: 15083878
    [No Abstract]   [Full Text] [Related]  

  • 29. Multichannel perimetric alterations in systemic lupus erythematosus treated with hydroxychloroquine.
    Piñero DP; Monllor B; Camps VJ; de Fez D
    J Optom; 2017; 10(2):135-138. PubMed ID: 27349992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine.
    Potter B
    Cutis; 1993 Oct; 52(4):229-31. PubMed ID: 8261810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use.
    Tsang-A-Sjoe MW; Bultink IE; Voskuyl AE
    Clin Exp Rheumatol; 2014; 32(1):95-100. PubMed ID: 24238093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular safety of hydroxychloroquine.
    Bernstein HN
    Ann Ophthalmol; 1991 Aug; 23(8):292-6. PubMed ID: 1952638
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Wolfe F; Marmor MF
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):775-84. PubMed ID: 20535788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings.
    Motarjemizadeh Q; Aidenloo NS; Abbaszadeh M
    Glob J Health Sci; 2015 Jun; 8(3):59-64. PubMed ID: 26493438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxychloroquine dosages should be calculated using lean body mass.
    Pautler SE
    Arch Ophthalmol; 2007 Sep; 125(9):1303-4; author reply 1304. PubMed ID: 17846384
    [No Abstract]   [Full Text] [Related]  

  • 36. Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy.
    Marmor MF; Melles RB
    Ophthalmology; 2014 Jun; 121(6):1257-62. PubMed ID: 24439759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxychloroquine toxicity despite normal dose therapy.
    Falcone PM; Paolini L; Lou PL
    Ann Ophthalmol; 1993 Oct; 25(10):385-8. PubMed ID: 8304691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of disease stage on progression of hydroxychloroquine retinopathy.
    Marmor MF; Hu J
    JAMA Ophthalmol; 2014 Sep; 132(9):1105-12. PubMed ID: 24922444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment.
    Rynes RI
    Am J Med; 1983 Jul; 75(1A):35-9. PubMed ID: 6869409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retinal toxicity found in a patient with systemic lupus erythematosus prior to 5 years of treatment with hydroxychloroquine.
    Chiang E; Jampol LM; Fawzi AA
    Rheumatology (Oxford); 2014 Nov; 53(11):2001. PubMed ID: 25172940
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.